Marshall Wace’s Cidara Therapeutics CDTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-222,763
| Closed | -$49.2M | – | 3237 |
|
|
2025
Q4 | $49.2M | Sell |
222,763
-12,547
| -5% | -$2.03M | 0.04% | 347 |
|
|
2025
Q3 | $22.5M | Sell |
235,310
-7,469
| -3% | -$477K | 0.02% | 604 |
|
|
2025
Q2 | $11.8M | Buy |
+242,779
| New | +$5.83M | 0.01% | 784 |
|
|
2023
Q3 | – | Sell |
-4,466
| Closed | -$101K | – | 2237 |
|
|
2023
Q2 | $101K | Buy |
4,466
+3,053
| +216% | +$71.7K | ﹤0.01% | 2322 |
|
|
2023
Q1 | $35.9K | Buy |
+1,413
| New | +$40.1K | ﹤0.01% | 2556 |
|
|
2022
Q1 | – | Sell |
-7,320
| Closed | -$185K | – | 3404 |
|
|
2021
Q4 | $185K | Sell |
7,320
-1,881
| -20% | -$58.6K | ﹤0.01% | 3183 |
|
|
2021
Q3 | $412K | Buy |
+9,201
| New | +$350K | ﹤0.01% | 2491 |
|
|
2020
Q1 | – | Sell |
-1,980
| Closed | -$152K | – | 1657 |
|
|
2019
Q4 | $152K | Buy |
+1,980
| New | +$90.6K | ﹤0.01% | 1395 |
|
Marshall Wace's CDTX Position: Q1 2026 in Review
Marshall Wace sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 222,763 shares — an estimated $49.2M sold.
Marshall Wace first reported a position in CDTX in Q4 2019 and held it in 8 quarters. The position peaked at $49.2M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.
- Marshall Wace reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
- Marshall Wace sold 222,763 Cidara Therapeutics shares in Q1 2026, an estimated $49.2M.
- Marshall Wace first reported a position in Cidara Therapeutics in Q4 2019 and held it in 8 quarters.
- Marshall Wace's Cidara Therapeutics position peaked at $49.2M in Q4 2025.
- 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.
Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.